This two part webinar features Dr. Li Huei Tsai from the Picower Institute at MIT and CST Development Scientist, Dr. Raphael Rozenfeld. Dr. Tsai discusses how modeling systems can be combined with immunolabeling and imaging techniques to unlock the mystery of Alzheimer's Disease. Dr Rozenfeld describes the rigorous validation procedure our antibodies undergo before being release, with special emphasis placed on our neuroscience portfolio. Check out the abstracts below and then click on the button to watch their exciting presentations.
Deciphering the Molecular Pathology of Alzheimer’s Disease:
Li-Huei Tsai, Ph. D, Picower Professor of Neuroscience, Director of the Picower Institute for Learning and Memory, Massachusetts Institute of Technology
Alzheimer’s disease presents stereotypical pathological features including the abundance of amyloid deposition and tauopathy. Affected brain regions also exhibit reactive astrogliosis, neuroinflammatory responses, and vascular pathology. Neuronal and synaptic loss is also evident. Various mouse lines have been created to investigate Alzheimer’s disease and most of the models exhibit a subset of the defining pathological features of the disease. In this webinar the speaker will discuss the use of Alzheimer’s disease transgenic mouse models to evaluate pathological features by both traditional immunohistochemistry and new tissue processing methods that enable whole- brain imaging. These immunolabeling methods further the investigation of molecular and neural circuit mechanisms of Alzheimer’s disease.
The Use of Highly Validated Antibodies to Study Neurodegenerative Disease: Raphael Rozenfeld, Ph. D.
Cell Signaling Technology's (CST) mission to produce high quality and rigorously validated antibodies extends to our neuroscience products. We use a comprehensive approach, from the selection of targets that are the most relevant to the scientists' current and future research, to the establishment of models for careful validation of the antibodies, and the formulation of ready-to-use antibodies for various experimental procedures relevant to the targets. The neuroscience portfolio comprises antibodies to cell type, sub-cellular compartment, and cell state markers; antibodies against important neurotransmitters; and a growing product line in the field of neurodegenerative diseases, such as Alzheimer's Disease, Parkinson's, Huntington's, and ALS. Our cutting- edge antibody development technologies allow us to generate highly sensitive and specific antibodies to various amyloid-beta peptides, Tau phosphorylation sites, and other disease-research relevant proteins. In this presentation, we will discuss CST's existing and up-coming products that will help neuroscientists' research efforts.